<DOC>
	<DOCNO>NCT02173457</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety Chiglitazar , compare Sitagliptin .</brief_summary>
	<brief_title>Study Chiglitazar Compare With Sitagliptin Type 2 Diabetes Patients</brief_title>
	<detailed_description>The efficacy safety compare Chiglitazar Sitagliptin treatment 24 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1 . Meet WHO Diagnostic Criteria Type 2 Diabetes ( publish 1999 ) ; 2 . HbA1c≥ 7.5 % ≤ 10.0 % control diet exercise ; 3 . Male female , age 18 70 year ; 4 . BMI 18.535kg/m2 ; 5 . Willing assigned treatment arm sign inform consent . 1 . Type 1 diabetes ; 2 . Treated oral injective antidiabetic drug screening , include insulin herb ; 3 . Fasting plasma glucose &gt; 13.3 mmol/L ( 240 mg/dL ) ; 4 . Resistant hypertension [ blood pressure goal despite adherence least 3 optimally dosed antihypertensive medication ( include diuretic ) different class , blood pressure control goal least different class drug ] ; 5 . Plasma triglyceride &gt; 500 mg/dL ( 5.65 mmol/L ) ; 6 . Is treat fibrates ; 7 . History diabetic ketoacidosis , diabetic hyperglycemic hyperosmolar syndrome , lactic acidosis , diabetic hypoglycemia ; currently combine retinopathy , diabetic nephropathy diabetic neuropathy ; 8 . Had transient ischemic attack , cerebrovascular accident unstable angina past 6 month ; 9 . History myocardial infarction conduct coronary angioplasty coronary artery bypass graft surgery ; 10 . Had pancreatic disease ; 11 . Heart failure ( NYHA classification Stage III IV ) , leave ventricular hypertrophy indicate ECG ; 12 . Hepatic disease hepatocirrhosis , active hepatitis , aspartate aminotransferase alanine aminotransferase &gt; 2.5 fold upper limit normal range ; 13 . Kidney diseases serum creatinine exceed normal range : male &gt; 133 μmol/L female &gt; 108 μmol/L ; 14 . Had malignancy past 5 year , include basal cell carcinoma ; 15 . Had currently receive treatment alter blood glucose metabolism , include limited diuretic , hormone ( corticotropin steroid ) , beta blocker ; 16 . Have disease alter blood glucose metabolism , include limited active hepatitis , hyperthyroidism , adrenal tumor ; 17 . Edema unknown reason ; 18 . Alcohol drug addiction ; 19 . Had participate drug ' clinical trial 3 month screen ; 20 . Pregnant lactic woman ; woman childbearing age able willing conduct contraception ; 21 . Any condition make investigator consider subject suitable participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chiglitazar</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>diabetes</keyword>
	<keyword>type 2 diabetes</keyword>
</DOC>